Laidlaw upgraded shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) from a hold rating to a buy rating in a research note released on Wednesday morning, Marketbeat.com reports. The firm currently has $90.00 price objective on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently commented on ICPT. BidaskClub cut Intercept Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, July 5th. Jefferies Group LLC started coverage on Intercept Pharmaceuticals in a report on Monday, July 10th. They set a buy rating and a $275.00 target price for the company. Zacks Investment Research upgraded Intercept Pharmaceuticals from a hold rating to a buy rating and set a $136.00 target price for the company in a report on Tuesday, July 11th. Cantor Fitzgerald restated an underweight rating and set a $69.00 target price (up from $60.00) on shares of Intercept Pharmaceuticals in a report on Monday, July 31st. Finally, Wedbush restated a buy rating on shares of Intercept Pharmaceuticals in a report on Monday, July 31st. Three analysts have rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of Hold and an average price target of $153.76.

Intercept Pharmaceuticals (NASDAQ ICPT) opened at $65.09 on Wednesday. The company has a debt-to-equity ratio of 2.05, a current ratio of 6.61 and a quick ratio of 6.61.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) EPS for the quarter, beating analysts’ consensus estimates of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative return on equity of 152.78% and a negative net margin of 344.74%. The company had revenue of $41.33 million during the quarter, compared to analysts’ expectations of $36.95 million. During the same period last year, the business posted ($3.59) EPS. Intercept Pharmaceuticals’s revenue for the quarter was up 697.9% on a year-over-year basis. analysts anticipate that Intercept Pharmaceuticals will post -13.79 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Intercept Pharmaceuticals, Inc. (ICPT) Raised to “Buy” at Laidlaw” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.watchlistnews.com/intercept-pharmaceuticals-inc-icpt-raised-to-buy-at-laidlaw/1678068.html.

In other news, CMO David Shapiro sold 1,250 shares of the firm’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $117.43, for a total transaction of $146,787.50. Following the sale, the chief marketing officer now owns 45,812 shares of the company’s stock, valued at approximately $5,379,703.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Lisa Bright sold 253 shares of the firm’s stock in a transaction dated Friday, August 25th. The stock was sold at an average price of $111.31, for a total value of $28,161.43. Following the sale, the insider now directly owns 23,324 shares in the company, valued at approximately $2,596,194.44. The disclosure for this sale can be found here. Insiders have sold a total of 4,069 shares of company stock worth $325,974 in the last three months. Corporate insiders own 9.20% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ICPT. Teachers Advisors LLC increased its position in Intercept Pharmaceuticals by 3.0% during the first quarter. Teachers Advisors LLC now owns 15,871 shares of the biopharmaceutical company’s stock worth $1,795,000 after buying an additional 461 shares during the period. PNC Financial Services Group Inc. increased its position in Intercept Pharmaceuticals by 0.7% during the first quarter. PNC Financial Services Group Inc. now owns 2,020 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 14 shares during the period. Legal & General Group Plc increased its position in Intercept Pharmaceuticals by 196.6% during the first quarter. Legal & General Group Plc now owns 5,413 shares of the biopharmaceutical company’s stock worth $612,000 after buying an additional 3,588 shares during the period. Vanguard Group Inc. increased its position in Intercept Pharmaceuticals by 4.7% during the first quarter. Vanguard Group Inc. now owns 1,270,984 shares of the biopharmaceutical company’s stock worth $143,749,000 after buying an additional 56,952 shares during the period. Finally, Geode Capital Management LLC increased its position in Intercept Pharmaceuticals by 12.8% during the first quarter. Geode Capital Management LLC now owns 144,130 shares of the biopharmaceutical company’s stock worth $16,301,000 after buying an additional 16,392 shares during the period. 82.81% of the stock is currently owned by institutional investors.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.